Meeting
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
Authors
Andrew J. Wagner
Dana-Farber Cancer Institute, Boston, MA
Andrew J. Wagner , William D. Tap , Anthony Frank Shields , Amita Patnaik , Rashmi Chugh , Gabriel Tinoco , Glenn Michelson , Oscar Alcantar , Michael Pelayo , Chao Zhang , Paul Severson , Eric Martin , Jonathan C. Trent II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT02401815
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11509)
DOI
10.1200/JCO.2018.36.15_suppl.11509
Abstract #
11509
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger
Poster
2023 ASCO Annual Meeting
Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.
First Author: William D. Tap
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu